Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
      Description

      This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

      Conditions
      Acute Myeloid LeukemiaMixed Lineage Acute LeukemiaMixed Lineage Leukemia Gene MutationMixed Phenotype Acute LeukemiaRefractory AMLAML with Mutated NPM1Acute Myeloid Leukemia RecurrentAcute Myeloid Leukemia, in RelapseNPM1 MutationKMT2ArMyeloid Sarcoma
      Talk to us
      RECRUITING
      A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
      Description

      Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

      Conditions
      Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute LeukemiaMixed Phenotype Acute LeukemiaAcute Leukemia of Ambiguous Lineage
      Talk to us